Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 11/20 | 0.39 |
| ▸ | AKT2 | P31751 | 7/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | SGK1 | O00141 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL235321 | 1.00 | AKT1 (0.39) | AKT1AKT2EGLN2ADORA2ATGFBR1 | |
| SCHEMBL2755329 | 1.00 | AKT1 (0.39) | AKT1AKT2EGLN2ADORA2ATGFBR1 | |
| SCHEMBL236064 | 0.93 | EGLN2 (0.38) | AKT1AKT2EGLN2KIT | |
| SCHEMBL2755333 | 0.93 | EGLN2 (0.38) | AKT1AKT2EGLN2KIT | |
| SCHEMBL236063 | 0.93 | EGLN2 (0.38) | AKT1AKT2EGLN2KIT | |
| SCHEMBL238057 | 0.90 | AKT1 (0.40) | AKT1AKT2KIT | |
| SCHEMBL238058 | 0.90 | AKT1 (0.40) | AKT1AKT2KIT | |
| SCHEMBL2755339 | 0.90 | AKT1 (0.40) | AKT1AKT2KIT | |
| SCHEMBL235957 | 0.89 | AKT1 (0.39) | AKT1AKT2EGLN2KIT | |
| SCHEMBL2755331 | 0.89 | AKT1 (0.39) | AKT1AKT2EGLN2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406250-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8614221-B2 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3R5 | AKT1 13/4885AKT2 4/4885EGLN2 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.